Salivary C-terminal Telopeptide Levels in Patients with Medication-related Osteonecrosis of the Jaw

Article Sidebar

pdf
Published: Apr 20, 2021
Keywords:
C-terminal telopeptide (CTX), Medication-related osteonecrosis of jaw (MRONJ), Bone biomarker

Main Article Content

Atchara Wongla
Mae Suai Hospital, Chiang Rai, Thailand
Worakanya Buranaphatthana
Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiangmai University, Thailand
Kathawut Tachasuttirut
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Chiang Mai University, Thailand

Abstract

Objective: To examine the level of saliva total protein and C-terminal telopeptide of type 1 collagen (CTX) in patients who receiving anti-resorptive drugs.


Patients and methods: A study compared in 3 groups (n=8): MRONJ patients, patients receiving anti-resorptive drugs without MRONJ development and participants without drug use. Unstimulated saliva samples were collected and analyzed levels of saliva total protein and CTX. One-way ANOVA was used for statistical analysis with p-value < 0.05.


Results: We found the lowest saliva CTX levels in MRONJ patients. A statistically significant reduction of the saliva CTX levels was found in MRONJ patients compared with at-risk patients (p=0.011).


Conclusion: CTX a bone resorption biomarker, can be detected in saliva. The level of saliva CTX in patients with MRONJ may decrease from the effect of anti-resorptive drugs. This suggests that saliva CTX might be used to predict the risk of MRONJ development in patients who are taking anti-resorptive drugs.

Article Details

How to Cite
Wongla, A., Buranaphatthana, W. ., & Tachasuttirut, K. (2021). Salivary C-terminal Telopeptide Levels in Patients with Medication-related Osteonecrosis of the Jaw. Chiang Mai Dental Journal, 42(1), 173–183. Retrieved from https://he01.tci-thaijo.org/index.php/cmdj/article/view/239894
Issue
Vol. 42 No. 1 (2021): January-April
Section
Original article

References

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-1117.

Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72(10): 1938-1956.

Kolokythas A, Karras M, Collins E, Flick W, Miloro M, Adami G. Salivary Biomarkers Associated With Bone Deterioration in atients With medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2015; 73(9): 1741-1747.

Hutcheson A, Cheng A, Kunchar R, Stein B, Sambrook P, Goss A. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J Oral Maxillofac Surg 2014;72(8): 1456-1462.

Pellegrini GG, Gonzales Chaves MM, Fajardo MA, et al. Salivary bone turnover markers in healthy pre- and postmenopausal women: daily and seasonal rhythm. Clin Oral Investig 2012; 16(2): 651-657.

Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone 2013; 57(1): 201-205.

Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev 2013; 26(4): 781-791.

Soutome S, Hayashida S, Funahara M, et al. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLoS One 2018; 13(7): e0201343.

Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27(32): 5356-5362.

Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012; 40(4): 303-309.

Otto S, Troltzsch M, Jambrovic V, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43(6): 847-854.

Potup P Wk, Klainak K, Piyarattanapan C, Pankla S.R. The Association Between Bone Mineral density and Biochemical Bone Turnover Markers in Women at Thapho Diatrict, Pitsanulok Province. Songkla Med J 2014; 32(2): 63-72.

Auzina D, Erts R, Lejniece S. Prognostic value of the bone turnover markers in multiple myeloma. Exp Oncol 2017; 39(1): 53-56.

Hinge M, Andersen KT, Lund T, et al. Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment. Haematologica 2016; 101(10): e419-e22.

Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112(3): 605-609.

Thumbigere-Math V, Michalowicz BS, de Jong EP, et al. Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw. Oral Dis 2015; 21(1): 46-56.

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015; 44(5): 568-585.

Shaila M, Pai GP, Shetty P. Salivary protein concentration, flow rate, buffer capacity and pH estimation: A comparative study among young and elderly subjects, both normal and with gingivitis and periodontitis. J Indian Soc Periodontol 2013; 17(1): 42-46.

Henskens YM, van der Velden U, Veerman EC, Nieuw Amerongen AV. Protein, albumin and cystatin concentrations in saliva of healthy subjects and of patients with gingivitis or periodontitis. J Periodontal Res 1993; 28(1): 43-48.

Johnson M. Protein Quantitation. Mater Methods 2012; 2: 115

Noble JE, Bailey MJ. Quantitation of protein. Methods Enzymol 2009; 463: 73-95.

Pongchaiyakul C, Kosulwat V, Charoenkiatkul S, Chailurkit LO, Rajatanavin R. The association of dietary calcium, bone mineral density and biochemical bone turnover markers in rural Thai women. J Med Assoc Thai 2008; 91(3): 295-302.

Gursoy UK, Kononen E, Huumonen S, et al. Salivary type I collagen degradation end-products and related matrix metalloproteinases in periodontitis. J Clin Periodontol 2013; 40(1): 18-25.

Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11 (Suppl 6): S30-44.

Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009; 24(3): 389-397.

Chubb SA. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem 2012; 45(12): 928-935.

Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110(4): 509-516.

Miricescu D, Totan A, Calenic B, et al. Salivary biomarkers: relationship between oxidative stress and alveolar bone loss in chronic periodontitis. Acta Odontol Scand 2014; 72(1): 42-47.

Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65(12): 2397-2410.

Thumbigere-Math V, Michalowicz BS, Hughes PJ, et al. Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2016; 74(4): 738-746.